History
Since it was founded in 1929, by Henri Beaufour, Ipsen has developed, and made available to patients, a number of products in Oncology, Neuroscience, Rare Diseases and Consumer Healthcare. Global footprint, acquisitions, partnerships, scientific collaborations and innovations: learn about the development of our group over the years.
2017
Early 2017: Acquisition of oncology assets from Merrimack Pharmaceuticals, a major step forward in bolstering Ipsen’s growing oncology presence and leveraging its oncology infrastructure in the United States.
Read more
Read more
2016
March 2016: Ipsen’s oncology pipeline was reinforced with the in-licensing of cabozantinib from Exelixis.
Read more
Read more
2015
April: Ipsen opened its new peptide-driven R&D center in Cambridge (USA).
Read more
Read more
2014
Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.
Read more
Read more
2013
Teijin Pharma Limited and Ipsen launched Somatuline® 60/90/120 mg for subcutaneous injection in Japan for the treatment of acromegaly and pituitary gigantism.
Read more
Read more
2012
Ipsen enters into a research partnership with Oncodesign to develop new therapeutic agents against LRRK2, a gene whose mutation is involved in Parkinson's disease.
Read more
Read more
2011
Ipsen announces a new development strategy based on three pillars
Read more
Read more
2010
Ipsen and Inspiration Biopharmaceuticals Inc. enter into a partnership to create a hemophilia franchise
Read more
Read more
2009
Ipsen and Galderma receive collective green light for Azzalure® from 15 European countries’ Health Authorities for the granting of national marketing authorizations for the treatment of glabellar lines
Read more
Read more
2008
Ipsen initiates a partnership with the Salk Institute for Biological Studies (San Diego, US) aimed at improving understanding of proliferative and degenerative diseases.
Read more
Read more
2007
The Group enters into a partnership with Galderma, for the development, promotion and distribution of the Group’s botulinum toxin type A in aesthetic medicine indications.
Read more
Read more
2006
Ipsen enters into an agreement with Medicis (now Valeant) to market its botulinum toxin in aesthetic medicine indications in the US, Canada and Japan.
Read more
Read more
2005
Ipsen’s shares are listed on Euronext Paris. Ipsen enters into a licensing agreement with Radius through which Radius acquires the exclusive worldwide rights (excluding Japan) to develop, manufacture and distribute Ipsen’s osteoporosis proprietary molecule.
2004
The Group opens a botulinum toxin manufacturing facility in Wrexham (United Kingdom).
2003
Ipsen and Teijin enter into an agreement to develop and market four Ipsen products, notably Somatuline® Autogel®, in Japan and a Teijin product for the treatment of gout in Europe.
2001-2002
Ipsen launches Somatuline® Autogel® in the UK, France followed by many other countries, strengthening Ipsen’s competitive position. To the Group’s knowledge, Somatuline® Autogel® is the first semi-solid formulation for injection without any excipient, since the active substance controls the sustained release.
2000
The Group is opening a manufacturing facility in China. This facility will manufacture Smecta® for the Chinese market, which is a reference treatment in the country.
1996
Ipsen launches Forlax®, a product used for the treatment of constipation.
1995
The Group launches Somatuline®, its sustained-release peptide for the treatment of acromegaly and neuroendocrine tumors in France.
1994
Ipsen acquires Speywood, the company that developed Dysport® for the treatment of movement disorders and various forms of muscular spasticity.
Read more
Read more
1992
Ipsen begins its development in China, with the opening of a representative office in Tianjin.
1983
The Group creates La Fondation Ipsen under the aegis of the Fondation de France. Its mission is to foster interactions between leading scientists in the field of life sciences.
1980
Ipsen initiates a partnership with Debiopharm....
Read more
Read more
1970
The Group enters an expansion phase with the launch of Ginkor®, Tanakan® and Smecta®. The Group creates Laboratoires Ipsen (Institute of Synthetic Products from Natural Extraction).
1969
The Group opens its first research facility in Les Ulis (France).
1954
The Group launches Citrate de Betaïne®, a product used in the symptomatic treatment of dyspepsia.
1929
Dr. Henri Beaufour creates Laboratoires Beaufour in Dreux (France) to launch Romarène®, a product derived from rosemary for the treatment of digestive disorders.
Last update 17/11/2017